Light Mode
$185.31 ↓ -2.38 (-1.27%) Trading Down from the previous close of $187.69, $2.47 below the day’s high of $187.78
+53.21 (+39.57%) / 6M
Momentum, market sentiment, and recent alerts
RVMD reads neutral: price sits above one of the two key moving averages, the 12-month move is +251.2%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
